Cargando…
Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment
BACKGROUND: Niemann–Pick disease type C (NPC) is a fatal neurodegenerative disorder caused by abnormal intracellular cholesterol trafficking. Cyclodextrins (CDs), the most promising therapeutic candidates for NPC, but with concerns about ototoxicity, are cyclic oligosaccharides with dual functions o...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449817/ https://www.ncbi.nlm.nih.gov/pubmed/37620691 http://dx.doi.org/10.1002/ctm2.1350 |
_version_ | 1785095043790405632 |
---|---|
author | Yamada, Yusei Fukaura‐Nishizawa, Madoka Nishiyama, Asami Ishii, Akira Kawata, Tatsuya Shirakawa, Aina Tanaka, Mayuko Kondo, Yuki Takeo, Toru Nakagata, Naomi Miwa, Toru Takeda, Hiroki Orita, Yorihisa Motoyama, Keiichi Higashi, Taishi Arima, Hidetoshi Seki, Takahiro Kurauchi, Yuki Katsuki, Hiroshi Higaki, Katsumi Minami, Kentaro Yoshikawa, Naoki Ikeda, Ryuji Matsuo, Muneaki Irie, Tetsumi Ishitsuka, Yoichi |
author_facet | Yamada, Yusei Fukaura‐Nishizawa, Madoka Nishiyama, Asami Ishii, Akira Kawata, Tatsuya Shirakawa, Aina Tanaka, Mayuko Kondo, Yuki Takeo, Toru Nakagata, Naomi Miwa, Toru Takeda, Hiroki Orita, Yorihisa Motoyama, Keiichi Higashi, Taishi Arima, Hidetoshi Seki, Takahiro Kurauchi, Yuki Katsuki, Hiroshi Higaki, Katsumi Minami, Kentaro Yoshikawa, Naoki Ikeda, Ryuji Matsuo, Muneaki Irie, Tetsumi Ishitsuka, Yoichi |
author_sort | Yamada, Yusei |
collection | PubMed |
description | BACKGROUND: Niemann–Pick disease type C (NPC) is a fatal neurodegenerative disorder caused by abnormal intracellular cholesterol trafficking. Cyclodextrins (CDs), the most promising therapeutic candidates for NPC, but with concerns about ototoxicity, are cyclic oligosaccharides with dual functions of unesterified cholesterol (UC) shuttle and sink that catalytically enhance the bidirectional flux and net efflux of UC, respectively, between the cell membrane and the extracellular acceptors. However, the properties of CDs that regulate these functions and how they could be used to improve treatments for NPC are unclear. METHODS: We estimated CD–UC complexation for nine CD derivatives derived from native α‐, β‐, and γ‐CD with different cavity sizes, using solubility and molecular docking analyses. The stoichiometry and complexation ability of the resulting complexes were investigated in relation to the therapeutic effectiveness and toxicity of each CD derivative in NPC experimental models. FINDINGS: We found that shuttle and sink activities of CDs are dependent on cavity size‐dependent stoichiometry and substituent‐associated stability of CD–UC complexation. The ability of CD derivatives to form 1:1 and 2:1 complexes with UC were correlated with their ability to normalize intracellular cholesterol trafficking serving as shuttle and with their cytotoxicity associated with cellular UC efflux acting as sink, respectively, in NPC model cells. Notably, the ability of CD derivatives to form an inclusion complex with UC was responsible for not only efficacy but ototoxicity, while a representative derivative without this ability negligibly affected auditory function, underscoring its preventability. CONCLUSIONS: Our findings highlight the importance of strategies for optimizing the molecular structure of CDs to overcome this functional dilemma in the treatment of NPC. |
format | Online Article Text |
id | pubmed-10449817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104498172023-08-26 Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment Yamada, Yusei Fukaura‐Nishizawa, Madoka Nishiyama, Asami Ishii, Akira Kawata, Tatsuya Shirakawa, Aina Tanaka, Mayuko Kondo, Yuki Takeo, Toru Nakagata, Naomi Miwa, Toru Takeda, Hiroki Orita, Yorihisa Motoyama, Keiichi Higashi, Taishi Arima, Hidetoshi Seki, Takahiro Kurauchi, Yuki Katsuki, Hiroshi Higaki, Katsumi Minami, Kentaro Yoshikawa, Naoki Ikeda, Ryuji Matsuo, Muneaki Irie, Tetsumi Ishitsuka, Yoichi Clin Transl Med Research Articles BACKGROUND: Niemann–Pick disease type C (NPC) is a fatal neurodegenerative disorder caused by abnormal intracellular cholesterol trafficking. Cyclodextrins (CDs), the most promising therapeutic candidates for NPC, but with concerns about ototoxicity, are cyclic oligosaccharides with dual functions of unesterified cholesterol (UC) shuttle and sink that catalytically enhance the bidirectional flux and net efflux of UC, respectively, between the cell membrane and the extracellular acceptors. However, the properties of CDs that regulate these functions and how they could be used to improve treatments for NPC are unclear. METHODS: We estimated CD–UC complexation for nine CD derivatives derived from native α‐, β‐, and γ‐CD with different cavity sizes, using solubility and molecular docking analyses. The stoichiometry and complexation ability of the resulting complexes were investigated in relation to the therapeutic effectiveness and toxicity of each CD derivative in NPC experimental models. FINDINGS: We found that shuttle and sink activities of CDs are dependent on cavity size‐dependent stoichiometry and substituent‐associated stability of CD–UC complexation. The ability of CD derivatives to form 1:1 and 2:1 complexes with UC were correlated with their ability to normalize intracellular cholesterol trafficking serving as shuttle and with their cytotoxicity associated with cellular UC efflux acting as sink, respectively, in NPC model cells. Notably, the ability of CD derivatives to form an inclusion complex with UC was responsible for not only efficacy but ototoxicity, while a representative derivative without this ability negligibly affected auditory function, underscoring its preventability. CONCLUSIONS: Our findings highlight the importance of strategies for optimizing the molecular structure of CDs to overcome this functional dilemma in the treatment of NPC. John Wiley and Sons Inc. 2023-08-24 /pmc/articles/PMC10449817/ /pubmed/37620691 http://dx.doi.org/10.1002/ctm2.1350 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Yamada, Yusei Fukaura‐Nishizawa, Madoka Nishiyama, Asami Ishii, Akira Kawata, Tatsuya Shirakawa, Aina Tanaka, Mayuko Kondo, Yuki Takeo, Toru Nakagata, Naomi Miwa, Toru Takeda, Hiroki Orita, Yorihisa Motoyama, Keiichi Higashi, Taishi Arima, Hidetoshi Seki, Takahiro Kurauchi, Yuki Katsuki, Hiroshi Higaki, Katsumi Minami, Kentaro Yoshikawa, Naoki Ikeda, Ryuji Matsuo, Muneaki Irie, Tetsumi Ishitsuka, Yoichi Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment |
title | Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment |
title_full | Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment |
title_fullStr | Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment |
title_full_unstemmed | Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment |
title_short | Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann–Pick disease type C treatment |
title_sort | different solubilizing ability of cyclodextrin derivatives for cholesterol in niemann–pick disease type c treatment |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449817/ https://www.ncbi.nlm.nih.gov/pubmed/37620691 http://dx.doi.org/10.1002/ctm2.1350 |
work_keys_str_mv | AT yamadayusei differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT fukauranishizawamadoka differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT nishiyamaasami differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT ishiiakira differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT kawatatatsuya differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT shirakawaaina differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT tanakamayuko differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT kondoyuki differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT takeotoru differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT nakagatanaomi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT miwatoru differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT takedahiroki differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT oritayorihisa differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT motoyamakeiichi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT higashitaishi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT arimahidetoshi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT sekitakahiro differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT kurauchiyuki differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT katsukihiroshi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT higakikatsumi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT minamikentaro differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT yoshikawanaoki differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT ikedaryuji differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT matsuomuneaki differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT irietetsumi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment AT ishitsukayoichi differentsolubilizingabilityofcyclodextrinderivativesforcholesterolinniemannpickdiseasetypectreatment |